These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 29959570)

  • 21. High FOXM1 expression was associated with bladder carcinogenesis.
    Liu D; Zhang Z; Kong CZ
    Tumour Biol; 2013 Apr; 34(2):1131-8. PubMed ID: 23325617
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer.
    Passoni N; Gayed B; Kapur P; Sagalowsky AI; Shariat SF; Lotan Y
    Urol Oncol; 2016 Nov; 34(11):485.e7-485.e14. PubMed ID: 27637323
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic role of N-cadherin expression in patients with non-muscle-invasive bladder cancer.
    Abufaraj M; Shariat SF; Haitel A; Moschini M; Foerster B; Chłosta P; Gust K; Babjuk M; Briganti A; Karakiewicz PI; Albrecht W
    Urol Oncol; 2017 May; 35(5):264-271. PubMed ID: 28214283
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Urinary Cell-Free DNA IQGAP3/BMP4 Ratio as a Prognostic Marker for Non-Muscle-Invasive Bladder Cancer.
    Xu Y; Kim YH; Jeong P; Piao XM; Byun YJ; Seo SP; Kang HW; Kim WT; Lee JY; Ryu DH; Choi JW; Kim IY; Moon SK; Choi YH; Yun SJ; Kim WJ
    Clin Genitourin Cancer; 2019 Jun; 17(3):e704-e711. PubMed ID: 31088707
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Connexin 43 expression predicts poor progression-free survival in patients with non-muscle invasive urothelial bladder cancer.
    Poyet C; Buser L; Roudnicky F; Detmar M; Hermanns T; Mannhard D; Höhn A; Rüschoff J; Zhong Q; Sulser T; Moch H; Wild PJ
    J Clin Pathol; 2015 Oct; 68(10):819-24. PubMed ID: 26251520
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Direct quantitative detection for cell-free miR-155 in urine: a potential role in diagnosis and prognosis for non-muscle invasive bladder cancer.
    Zhang X; Zhang Y; Liu X; Fang A; Wang J; Yang Y; Wang L; Du L; Wang C
    Oncotarget; 2016 Jan; 7(3):3255-66. PubMed ID: 26657502
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
    Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
    Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HMOX1 is an important prognostic indicator of nonmuscle invasive bladder cancer recurrence and progression.
    Yim MS; Ha YS; Kim IY; Yun SJ; Choi YH; Kim WJ
    J Urol; 2011 Feb; 185(2):701-5. PubMed ID: 21168882
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A gene expression signature of FOXM1 predicts the prognosis of hepatocellular carcinoma.
    Song BN; Chu IS
    Exp Mol Med; 2018 Jan; 50(1):e418. PubMed ID: 29303511
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overexpression of G2 and S phase-expressed-1 contributes to cell proliferation, migration, and invasion via regulating p53/FoxM1/CCNB1 pathway and predicts poor prognosis in bladder cancer.
    Liu A; Zeng S; Lu X; Xiong Q; Xue Y; Tong L; Xu W; Sun Y; Zhang Z; Xu C
    Int J Biol Macromol; 2019 Feb; 123():322-334. PubMed ID: 30414902
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic significance of heme oxygenase-1, S100 calcium-binding protein A4, and syndecan-1 expression in primary non-muscle-invasive bladder cancer.
    Kim JH; Park J
    Hum Pathol; 2014 Sep; 45(9):1830-8. PubMed ID: 24957789
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Methylation of HOXA9 and ISL1 Predicts Patient Outcome in High-Grade Non-Invasive Bladder Cancer.
    Kitchen MO; Bryan RT; Haworth KE; Emes RD; Luscombe C; Gommersall L; Cheng KK; Zeegers MP; James ND; Devall AJ; Fryer AA; Farrell WE
    PLoS One; 2015; 10(9):e0137003. PubMed ID: 26332997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.
    Bertz S; Otto W; Denzinger S; Wieland WF; Burger M; Stöhr R; Link S; Hofstädter F; Hartmann A
    Eur Urol; 2014 Jan; 65(1):218-26. PubMed ID: 22633802
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ΔNp63 transcript loss in bladder cancer constitutes an independent molecular predictor of TaT1 patients post-treatment relapse and progression.
    Papadimitriou MA; Avgeris M; Levis PK; Tokas T; Stravodimos K; Scorilas A
    J Cancer Res Clin Oncol; 2019 Dec; 145(12):3075-3087. PubMed ID: 31595333
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Urinary expression of let-7c cluster as non-invasive tool to assess the risk of disease progression in patients with high grade non-muscle invasive bladder Cancer: a pilot study.
    Spagnuolo M; Costantini M; Ferriero M; Varmi M; Sperduti I; Regazzo G; Cicchillitti L; Díaz Méndez AB; Cigliana G; Pompeo V; Russo A; Laquintana V; Mastroianni R; Piaggio G; Anceschi U; Brassetti A; Bove A; Tuderti G; Flammia RS; Gallucci M; Simone G; Rizzo MG
    J Exp Clin Cancer Res; 2020 Apr; 39(1):68. PubMed ID: 32303246
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients.
    Breyer J; Wirtz RM; Otto W; Erben P; Worst TS; Stoehr R; Eckstein M; Denzinger S; Burger M; Hartmann A
    Cancer Immunol Immunother; 2018 Mar; 67(3):403-412. PubMed ID: 29150702
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Splicing Factor PTBP1 Promotes Expression of Oncogenic Splice Variants and Predicts Poor Prognosis in Patients with Non-muscle-Invasive Bladder Cancer.
    Bielli P; Panzeri V; Lattanzio R; Mutascio S; Pieraccioli M; Volpe E; Pagliarulo V; Piantelli M; Giannantoni A; Di Stasi SM; Sette C
    Clin Cancer Res; 2018 Nov; 24(21):5422-5432. PubMed ID: 30012566
    [No Abstract]   [Full Text] [Related]  

  • 38. Neutrophil-to-lymphocyte ratio predicts progression and recurrence of non-muscle-invasive bladder cancer.
    Mano R; Baniel J; Shoshany O; Margel D; Bar-On T; Nativ O; Rubinstein J; Halachmi S
    Urol Oncol; 2015 Feb; 33(2):67.e1-7. PubMed ID: 25060672
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Construction of predictive models for recurrence and progression in >1000 patients with non-muscle-invasive bladder cancer (NMIBC) from a single centre.
    Ali-El-Dein B; Sooriakumaran P; Trinh QD; Barakat TS; Nabeeh A; Ibrahiem el-HI
    BJU Int; 2013 Jun; 111(8):E331-41. PubMed ID: 23445082
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder: implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer.
    Garczyk S; Bischoff F; Schneider U; Golz R; von Rundstedt FC; Knüchel R; Degener S
    Virchows Arch; 2021 Aug; 479(2):325-335. PubMed ID: 33650041
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.